Forward PE Ratio: 7.65
The forward PE ratio is 7.65 as of Thursday, July 9, 2026.
Forward PE Ratio (7.65) = Close Price ($11.98) / Consensus Forward EPS ($1.57)
WBA Forward PE Ratio Metrics
FORWARD PE RATIO
7.65
WBA Competitors' Forward PE Ratio
Walgreens Boots Alliance, Inc.
Market Cap
$10.37B
Forward PE Ratio
7.65
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Walgreens Boots Alliance, Inc. (WBA) | $10.37B | 7.65 |
| Tempus AI, Inc. (TEM)vs › | $10.73B | N/A |
| Insulet Corp. (PODD)vs › | $10.96B | 24.29 |
| Universal Health Services, Inc. (UHS)vs › | $9.72B | 6.66 |
| Bio-Techne Corporation (TECH)vs › | $11.14B | 36.89 |
| Henry Schein, Inc. (HSIC)vs › | $9.55B | 15.56 |
| Charles River Laboratories International, Inc. (CRL)vs › | $11.25B | 20.18 |
| Baxter International Inc. (BAX)vs › | $11.60B | 11.45 |
| Molina Healthcare, Inc. (MOH)vs › | $12.09B | 45.00 |
| Revvity, Inc. (RVTY)vs › | $12.60B | 20.86 |
Trailing vs Forward
Trailing P/E
N/A
reported TTM EPS
Forward P/E
7.7
consensus next-FY EPS
Forward P/E by Fiscal Year
View All Analyst EstimatesAt today's $11.98 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-08-31 | $1.57 | $1.13 – $1.73 | 5 | 7.6x |
| 2027-08-31 | $1.67 | $-0.37 – $2.78 | 3 | 7.2x |
| 2028-08-31 | $1.80 | $1.66 – $1.89 | 1 | 6.7x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
Forward PE Ratio Formula & Definition
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Forward PE Ratio FAQ
- What is the forward PE ratio for Walgreens Boots Alliance, Inc. (WBA)?
- The forward PE ratio for WBA stock is 7.65.
Related Metrics
About Walgreens Boots Alliance, Inc.
Walgreens Boots Alliance, Inc., established in 1901 and based in Deerfield, Illinois, operates as a leading global retailer focused on pharmacy, health, and beauty products. Its business activities are organized into two primary divisions: the United States and International. In the United States, the company dispenses prescription drugs and offers a diverse selection of retail goods. This includes items for health, wellness, beauty, and personal care, alongside general merchandise and consumable products, all available through its extensive network of retail drugstores. The U.S. segment also provides specialized central pharmacy services and mail delivery options for prescriptions. As of August 31, 2021, this division managed 8,965 retail outlets under the Walgreens and Duane Reade banners, complemented by five specialty pharmacies. The International segment focuses on the sale of prescription medications, health and wellness items, beauty products, personal care essentials, and other consumer goods. These are sold through its pharmacy-centric health and beauty retail locations, optical practices, its online platform boots.com, and an integrated mobile application. Additionally, this segment engages in pharmaceutical wholesale and distribution operations within Germany. By August 31, 2021, the international portfolio included 4,031 retail stores operating under brands such as Boots, Benavides, and Ahumada, located across countries including the United Kingdom, Thailand, Norway, the Republic of Ireland, the Netherlands, Mexico, and Chile. It also oversaw 548 optical practices, with 160 of these operating as franchises.
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Timothy C. Wentworth